ClinicalTrials.gg

Spinocerebellar Degenerations clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 49 studies for Spinocerebellar Degenerations across more than 10 countries. 15 are recruiting or about to start. 29 of them are mainly about Spinocerebellar Degenerations (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-12. Counting its 4 narrower conditions too, such as Friedreich Ataxia: 295 studies, 69 open.

Status

Completed
24
Recruiting
9
Not yet recruiting
6
Active, not recruiting
5
Terminated
2
Status unknown
2

Phase

Phase 2
19
Phase 3
9
Phase 1
7
Phase 4
1

Where

United States
18
Japan
11
China
10
Italy
7
Spain
7
France
6

Who develops what

Add Spinocerebellar Degenerations to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 2 programs from 2 companies, 1 with this as their studies’ main aim; 1 with a live phase 3 study; 1 primary completion in the next 12 months.

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

DrugLeading trial sponsor · rightsCompanies, last 5 years
pembrolizumabRecent, limited
Evidence
  • NCT07808151 · Solstice Oncology, Inc. · Phase 2 · live · background · “Pembrolizumab” · registered Sep 2026
Merck & Co., Inc74% of its industry studiesUS: Merck & Co., Inc (FDA 2014)EU: Merck & Co., Inc (EMA 2015)11 study
regorafenibRecent, limited
Evidence
  • NCT05328908 · Bristol-Myers Squibb · Phase 3 · background · “Regorafenib” · registered Mar 2022
Bayer80% of its industry studiesUS: Bayer (FDA 2012)EU: Bayer (EMA 2013)11 study
trifluridine tipiracil drug combinationRecent, limited
Evidence
  • NCT05328908 · Bristol-Myers Squibb · Phase 3 · comparator · “TAS-102” · registered Mar 2022
Otsuka Holdings Co., Ltd.52% of its industry studies11 study

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

The 2 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (1)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

  • 31 Mar 2027 est.rovatirelin · Kissei Pharmaceutical Co., Ltd. · Phase 3 main aimNCT07040137 Confirmatory Study 3 of KPS-0373 in Patients With Spinocerebellar Degeneration — primary endpoint: Change from baseline in SARA total score at 24 weeks of treatment period · 142 enrolled

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Spinocerebellar Degenerations studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug classes tested here Immune checkpoint inhibitors 5 open

Coming up

3studies finish main data collection within a year1 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

All 3, phase 3 first

Who these studies take

Of the 9 Spinocerebellar Degenerations studies recruiting now, 5 (56%) set no upper age limit and 3 (33%) stop at 75 or younger. 4 (44%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 1 (11%) take healthy volunteers.

Recruiting studies that take each age, of 9
AgeWomenMen
104 (44%)4 (44%)
188 (89%)8 (89%)
309 (100%)9 (100%)
409 (100%)9 (100%)
509 (100%)9 (100%)
658 (89%)8 (89%)
756 (67%)6 (67%)
856 (67%)6 (67%)

Across all 49 studies, recruiting or not: 16% stop at 75 or younger and 12% at 65; 18% take children; 0% are for women only and 0% for men only; 2% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

What changed recently

From the registry's own updates since Oct 19, 2026.

Studies

Recruiting first, then most recently updated. Showing 49 of 49. search them.